GET THE APP

Adalimumab in hidradenitis suppurativa - what really matters? : a multi-centre cross sectional study

Journal Plastic Surgery and Cosmetology.

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Adalimumab in hidradenitis suppurativa - what really matters? : a multi-centre cross sectional study

Hidradenitis suppurativa (HS) is a chronic relapsing and remitting condition which is characterised by inflammation resulting in painful nodules and abscesses and can prove difficult to treat, especially as patients experience social and psychological complexities. HS is traditionally managed with lifestyle modifications and antibiotics. Introduction of biologic therapy has revolutionised treatment, with benefits in reducing pain, discharge and nodule recurrence.

Adalimumab is a monoclonal antibody used for resistant cases of HS. Multiple studies have shown remarkable clinical efficacy of Adalimumab in reducing the severity of physical symptoms, but few have explored in depth the psychological and social effects of the drug.

Special Features

Full Text

View

Track Your Manuscript

Media Partners

Associations